Principal Financial Group Inc. Buys 32,485 Shares of Organon & Co. (NYSE:OGN)

Principal Financial Group Inc. raised its position in shares of Organon & Co. (NYSE:OGN) by 2.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,248,797 shares of the company’s stock after purchasing an additional 32,485 shares during the period. Principal Financial Group Inc. owned 0.48% of Organon & Co. worth $18,632,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Prospera Private Wealth LLC purchased a new position in shares of Organon & Co. during the 3rd quarter valued at $25,000. Horizon Bancorp Inc. IN lifted its holdings in Organon & Co. by 2,401.5% during the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after purchasing an additional 1,585 shares during the last quarter. Abich Financial Wealth Management LLC boosted its position in Organon & Co. by 5,646.3% during the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after purchasing an additional 2,315 shares during the period. MassMutual Private Wealth & Trust FSB increased its stake in shares of Organon & Co. by 32.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after purchasing an additional 672 shares in the last quarter. Finally, Versant Capital Management Inc increased its stake in shares of Organon & Co. by 92.2% in the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after purchasing an additional 1,324 shares in the last quarter. 77.43% of the stock is owned by institutional investors.

Organon & Co. Stock Performance

NYSE OGN opened at $15.08 on Tuesday. The company’s 50 day simple moving average is $15.37 and its two-hundred day simple moving average is $17.22. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The stock has a market capitalization of $3.88 billion, a PE ratio of 4.53, a P/E/G ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be given a dividend of $0.28 per share. The ex-dividend date is Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.43%. Organon & Co.’s dividend payout ratio (DPR) is presently 33.63%.

Wall Street Analyst Weigh In

A number of analysts recently commented on OGN shares. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Barclays cut their price target on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Finally, Morgan Stanley reduced their price target on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Organon & Co. presently has an average rating of “Hold” and a consensus price target of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.